Category:

GeoVax Labs (GOVX) – Raising Price Target To $10 Based On Program Progress

Posted on by cpereira@noblefcm.com


Monday, August 19, 2024

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

GeoVax Has Made Substantial Clinical and Manufacturing Process. We are raising our Price Target on GEOX to $10 based on the recent progress that has driven the stock through our previous $6 target. The company recently announced a DARPA grant for CM04S1 and its Phase 2 plans for Gedeptin in HNSCC. Last week, Mpox news highlighted recent advances in GeoVax’s manufacturing platform and its MVA-based vaccine for smallpox and Mpox.

Mpox News Draws Attention To GeoVax’s MVA Manufacturing Platform. On August 14, WHO declared Mpox to be a “public health emergency of international concern”, or PHEIC, due to a new type of Mpox (formerly monkeypox) spreading in West Africa. The new type is more infectious and more fatal than the type seen 2022. The previous virus spread through sexual contact (bodily fluids), while the current strain has also spread to health care workers through contact with patients’ clothing and bedding.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Wall Street Rallies: Stocks Poised for Best Week of 2024 as Recession Fears Fade

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– S&P 500 and Nasdaq on track for seventh consecutive day of gains
– Markets recovering from recent downturn, buoyed by positive economic data
– Investors eye Jackson Hole symposium for insights on Fed’s rate cut trajectory

Wall Street is gearing up to close its most impressive week of 2024, with major indices rebounding strongly as concerns about an economic slowdown dissipate. The S&P 500 and Nasdaq are set to mark their seventh straight day of gains, erasing losses from a recent market tumble and signaling renewed investor confidence.

This remarkable turnaround comes on the heels of encouraging economic data that has alleviated fears of an imminent recession. The week’s positive momentum has been fueled by reports indicating that inflation continues to trend downward towards the Federal Reserve’s target, while American consumer spending remains robust.

Oliver Pursche, senior vice president at Wealthspire Advisors, commented on the market’s resilience: “It has been a great week, and it has been a great year. There’s been some volatility, but major indices are all up nicely. What we saw a couple weeks ago was the market blowing off some steam.”

The rally has been broad-based, with the financial sector leading gains among S&P 500 components. However, not all sectors have participated equally, with real estate showing some weakness. This divergence highlights the nuanced nature of the current market environment, where investors are carefully weighing various economic indicators and sector-specific factors.

Looking ahead, market participants are eagerly anticipating the upcoming Jackson Hole Economic Symposium. This annual gathering of global central bank officials, scheduled for next week, could provide crucial insights into future monetary policy decisions. Federal Reserve Chair Jerome Powell’s keynote speech on Friday is expected to be a focal point, potentially setting expectations for the U.S. interest rate trajectory.

Austan Goolsbee, President of the Federal Reserve Bank of Chicago, has already set a dovish tone, cautioning against maintaining restrictive policy longer than necessary. This sentiment, coupled with recent economic data, has led to increased speculation about potential rate cuts. According to CME’s FedWatch tool, there’s a 74.5% probability that the Fed will implement a 25 basis point cut at its September meeting.

The market’s optimism is reflected in the performance of major indices. As of early afternoon trading, the Dow Jones Industrial Average was up 0.27%, the S&P 500 gained 0.21%, and the Nasdaq Composite added 0.25%. These gains put all three indices on track for their most substantial weekly percentage increases since October.

Despite the overall positive sentiment, some individual stocks faced headwinds. Applied Materials saw its shares decline by 1.7% despite forecasting stronger-than-expected fourth-quarter revenue. Similarly, packaging company Amcor’s U.S.-listed shares dropped 4.9% following a larger-than-anticipated decline in fourth-quarter sales.

As the trading week draws to a close, the market’s resilience in the face of recent volatility has been noteworthy. The shift from recession fears to recovery hopes underscores the fluid nature of investor sentiment and the importance of economic data in shaping market narratives.

With the Jackson Hole symposium on the horizon, investors will be keenly watching for any signals that might influence the Fed’s approach to monetary policy. The coming weeks could prove crucial in determining whether this rally has staying power or if new challenges lie ahead for Wall Street.

Release – Comtech Relocates Corporate Headquarters to Chandler, AZ

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on CMTL

Arizona Governor, Chandler Mayor, and Local Leaders to Attend August 16 Ribbon Cutting to Celebrate the Relocation of Comtech’s Headquarters to Arizona

CHANDLER, Ariz. – Aug. 16, 2024– Comtech (NASDAQ: CMTL) (the “Company”), a global technology leader, today announced the relocation of its corporate headquarters from Melville, NY to Chandler, AZ. Comtech’s new corporate headquarters in Chandler boasts approximately 150,000 square feet of state-of-the-art office, engineering and manufacturing space that is designed to enhance operations, improve collaboration and accelerate the delivery of new technologies, systems and services to a variety of customers across global markets.

The decision to relocate Comtech’s headquarters to Chandler, first disclosed in March 2024, is rooted in the Company’s continued commitment to optimizing its corporate infrastructure and enhancing Comtech’s culture of innovation. The City of Chandler is already home to several of Comtech’s largest customers and provides easy access to a leading technology corridor that is renowned for yielding the talent needed to develop and execute the Company’s vision, which is centered on delivering trusted and resilient communications solutions to commercial and government customers across the globe.

“Chandler has established itself as a leading technology corridor in the United States,” said John Ratigan, Interim CEO of Comtech. “We are thrilled to expand our footprint in Arizona and excited to benefit from the City of Chandler’s continued commitment to innovation. This strategic move marks a significant milestone for the Company, and our new headquarters will play a central role in helping Comtech deliver new resilient, network agnostic, software-defined communications capabilities to some of the world’s most demanding customers, including the Department of Defense (“DoD”).”

To mark the milestone, the company will host a formal ribbon cutting ceremony today with Arizona Governor, Katie Hobbs, Chandler Mayor, Kevin Hartke, and other Arizona business and community leaders. While Comtech started welcoming employees to its new Chandler office in 2023, the Company has had a presence in Arizona and served local commercial, defense and government customers for over 25years.

“Today marks a momentous day for Arizona as we welcome Comtech, a leading global technology company, to its new home in Chandler,” said Arizona Governor Katie Hobbs. “Comtech’s Chandler headquarters will bring enhanced economic growth opportunities and highlights Arizona’s attractive business environment and reputation as a top hub for innovation and technology. We are proud to support Comtech in their new chapter and look forward to supporting Comtech’s success in Arizona.”

The technologies, solutions and services developed at Comtech’s Chandler headquarters currently serve a variety of commercial and government customers, including the U.S. government, the DoD, humanitarian agencies, satellite service providers, some of the nation’s largest cellular carriers, cruise lines, and emergency response agencies, among others. New offerings being developed at Comtech’s Chandler headquarters are designed to expand access to new connectivity services; connect the end users in some of the world’s most challenging geographic regions; and empower customers with new, integrated communications capabilities that can significantly enhance decision making capabilities when seconds matter most.

“I am thrilled that Comtech has chosen Chandler as the site for their new global headquarters,” said U.S. Representative Greg Stanton. “The investment Comtech is making in our community underscores the potential they see in our workforce, our infrastructure, and our economic climate. With over 50 years of technology leadership across global satellite, space, terrestrial, and wireless markets, Comtech is uniquely positioned to lead the way in connecting the unconnected and empowering the world with new technologies and services.”

Comtech is committed to continuing to enhance the Chandler community through local partnerships, strategic sponsorships and workforce development programs. Over the past two years, a variety of Arizona students participated in the Company’s summer internship program. In February, in partnership with the Society of Women Engineers at Arizona State University, Comtech sponsored and participated in the annual Chandler Innovation Fair. Last October, the Chandler Chamber of Commerce recognized Comtech as one of the Top 100 businesses in the city. And in March 2023, Comtech hosted its first-ever EXCHANGE event, an educational series inspiring woman of all ages to pursue STEAM career fields, in Chandler.

“We are excited to join Comtech in celebrating their new global headquarters in Chandler,” said Chandler Mayor Kevin Hartke. “Publicly traded headquarters do not relocate often, but we have found that Chandler’s robust talent pipeline and pro-business operating environment make a compelling case for corporate decision makers. Comtech adds to a growing list of headquarters that have landed in Chandler over the last few years. It has been a real pleasure working with the Comtech team during this process and we look forward to building a strong partnership in the years to come.”

As Comtech’s presence in Arizona continues to grow, the Company is currently hiring for a variety of Chandler-based positions. If you are interested in joining Comtech, please visit the careers page of the Company’s website for more information.

To learn more about the Company’s new Chandler, Arizona headquarters, please visit: https://comtech-ssd.hs-sites.com/az24

About Comtech

Comtech Telecommunications Corp. (Comtech) is a leading global technology company providing terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. Comtech leverages our global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions.For more information, please visit www.comtech.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results and performance could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

Investor Relations

Maria Ceriello

631-962-7102

investors@comtech.com

Media Contact

Jamie Clegg

480-532-2523

jamie.clegg@comtech.com

Release – Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on TNXP

World Health Organization (WHO) has declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) 1

Tonix’s live virus vaccine candidate, TNX-801, is designed to provide long-term protection from mpox and smallpox with one dose

TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with intratracheal monkeypox virus

Clade II mpox is now endemic in the U.S. with >30,000 cases reported since May 20222 and Clade I mpox is endemic in the Democratic Republic of the Congo3

Tonix’s vaccine platform has been selected by NIH’s Project NextGen for clinical testing

CHATHAM, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has reiterated its commitment to advance development of its live attenuated virus vaccine, TNX-801 (recombinant horsepox virus), for preventing mpox (formerly known as monkeypox) and other infectious diseases. On August 14, 2024, the World Health Organization (WHO) determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern, the second such declaration in the past two years called in response to an mpox outbreak. The current outbreak was caused by Clade 1 monkeypox virus, while the 2022 outbreak was Clade 2 monkeypox virus.

TNX-801 is a live replicating attenuated vaccine candidate based on horsepox that is believed to provide immune protection with better tolerability than 20th century vaccinia viruses. The same vaccine platform upon which TNX-801 is based was selected by the U.S. National Institutes of Health (NIH) for Project NextGen for an engineered version that expresses the spike protein of SARS-CoV-2.

As previously disclosed, TNX-801 protected animals against lethal challenge with intratracheal Clade 1 monkeypox virus4. After a single-dose vaccination, TNX-801 prevented clinical disease and lesions and also decreased shedding in the mouth and lungs of non-human primates4. These findings are consistent with mucosal immunity and suggest the ability to block forward transmission, similar to Dr. Edward Jenner’s vaccinia vaccine, which eradicated smallpox and kept mpox out of the human population.

“The recent WHO declaration underscores the urgent need for additional treatments to stop these outbreaks and save lives,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “We are motivated to advance development for our mpox vaccine with urgency given the global public health emergency. Preclinical trials demonstrate that TNX-801 combines immune protection with improved tolerability and safety compared to other vaccines based on orthopoxviruses, and is administered with a single dose which has advantages over two-dose regimens. The durability of protection from 19th century live virus vaccinia vaccines suggests that our attenuated TNX-801 will not require multiple repeated doses at six-month intervals like mRNA vaccines. Also, the stability of live virus vaccines eliminates the need for ultra-cold storage which complicates the widespread use of mRNA vaccines in Africa, where they are needed most right now.”

The global mpox outbreak, which commenced in 2022, has affected over 90,000 persons in countries where mpox had previously not been endemic, including Europe and the U.S. The spread of Clade IIb strain mpox in 2022 underscores the pandemic potential of mpox. Unlike Clade IIb mpox, the Clade I strain of mpox appears to be spreading to countries neighboring the Democratic Republic of the Congo. Clade I mpox is typically associated with approximately 20 times the case fatality rates than Clade IIb mpox in Africa. According to the U.S. Centers for Disease Control and Prevention (CDC), and other experts, there is a significant risk that the deadlier Clade I strain may appear in the U.S.2,8

Further, the Bipartisan Commission on Biodefense recently highlighted the renewed dual threats of a more virulent mpox epidemic and a smallpox re-introduction from lab accidents or bad actors9. The National Academies of Science, in its review of smallpox preparedness, highlighted the need for new single dose vaccines, like TNX-801 against smallpox10.

About TNX-801* and Tonix’s RPV Platform

TNX-801 (recombinant horsepox virus) is a live virus vaccine for percutaneous administration that is being developed to target smallpox, and mpox (monkeypox). TNX-801 is also the basis of the RPV platform based on a horsepox vector, which is being adapted as a COVID-19 vaccine, term TNX-1800*. Horsepox is a live replicating, attenuated virus that has been shown to be >1,000-fold more attenuated than 20th century vaccinia (VACV) strains in immunocompromised mice. Horsepox and the vaccinia vaccine viruses are closely related orthopoxviruses that are believed to share a common ancestor. Molecular analysis shows that horsepox is closer than modern vaccinia vaccines in DNA sequence to the vaccine discovered and disseminated by Dr. Edward Jenner. Live replicating orthopoxviruses, like vaccinia or horsepox, can be engineered to express foreign genes and have been explored as platforms for vaccine development because they possess; (1) large packaging capacity for exogenous DNA inserts, (2) precise virus-specific control of exogenous gene insert expression, (3) lack of persistence or genomic integration in the host, (4) strong immunogenicity as a vaccine, (5) ability to rapidly generate vector/insert constructs, (6) readily manufacturable at scale, and (7) ability to provide direct antigen presentation. Relative to vaccinia, horsepox has substantially decreased virulence in mice. The current formulation is a frozen liquid, but we believe that future lyophilized versions can be stored and shipped at standard refrigeration. Horsepox-based vaccines are designed to be single dose, vial-sparing vaccines that can be administered without sterile injection, manufactured using conventional cell culture systems with the potential for mass scale production, and packaged in multi-dose vials.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix recently announced the U.S. Department of Defense (DoD), Defense Threat Reduction Agency (DTRA) awarded it a contract for up to $34 million over five years in an Other Transaction Agreement (OTA) to develop TNX-4200 small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. The company’s Good Manufacturing Practice (GMP)-capable advanced manufacturing facility in Dartmouth, MA was purpose-built to manufacture TNX-801 and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

1WHO Press Release August 14, 2024. “WHO Director-General declares mpox outbreak a public health emergency of international concern”. URL: www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern (accessed 8-15-24)
2McQuiston JH, et al. U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo. 2024, MMWR Morb Mortal Wkly Rep: United States. p. 435-440
3CDC. 2022-2023 Mpox: US Map and Case Count. https://www.cdc.gov/poxvirus/mpox/response/2022/us-map.html
4Noyce RS, et al. Viruses. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356
5Trefry, SV et al. bioRxiv 2023.10.25.564033; https://doi.org/10.1101/2023.10.25.564033
6Awasthi M, et al. Viruses. 2023 Oct 21;15(10):2131. doi: 10.3390/v15102131.
7Awashti M et al Vaccines (Basel). 2023 Nov 2;11(11):1682. doi:10.3390/vaccines11111682.
8World Health Organization SAGE meeting highlights on updated mpox vaccine recommendations. 2024, March
9Bipartisan Commission on Biofense. Box the Pox: Reducing the risk of Smallpox and Other Orthopoxviruses, Washington: 2024
10U.S. National Academies of Science. Future State of Smallpox Medical Countermeasures. Washington: 2024

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact

Lisa DeScenza
LaVoieHealthScience
ldescenza@lavoiehealthscience.com
(617) 351-0243

Source: Tonix Pharmaceuticals Holding Corp.

Released August 16, 2024

Xcel Brands (XELB) – Near Term Moving Parts, But 2025 Revenue Trends Appear Favorable

Posted on by cpereira@noblefcm.com


Friday, August 16, 2024

Xcel Brands, Inc. 1333 Broadway 10th Floor New York, NY 10018 United States https:/Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 84 Key Executives Name Title Pay Exercised Year Born Mr. Robert W. D’Loren Chairman, Pres & CEO 1.27M N/A 1958 Mr. James F. Haran CFO, Principal Financial & Accou

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 Results. Total company revenues of $2.95 million was in line with our $3.0 million estimate. Adj. EBITDA, which was essentially flat at a loss of $40,000, was in line with our loss estimate of $44,000. Q2 reflected sequential quarterly improvement from the Q1 adj. EBITDA loss of $1.6 million. 

A Lot of moving parts. We anticipate some noise in Q3 from the absence of Lori Goldstein’s brand. But, we expect a lift in Q4 revenue from holiday spending, particularly in Jewelry. Furthermore, the company has a lot in the pipeline; a launch of a food and kitchen products brand in Q1, expansion of Christie Brinkley’s brand, TWRHLL, including a possible launch into two big box retailers, and contributions from Halston, slated for Spring of 2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Traws Pharma (TRAW) – Traws Reports 2Q24 and Gives Post-Acquisition Update

Posted on by cpereira@noblefcm.com


Friday, August 16, 2024

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in a combination trial with estrogen blockade in advanced endometrial cancer. Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova is also evaluating opportunities for combination studies with narazaciclib in additional indications. Onconova’s product candidate rigosertib is being studied in multiple investigator-sponsored studies. These studies include a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer, a Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC), and a Phase 2 trial evaluating rigosertib in combination with pembrolizumab in patients with metastatic melanoma.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Operations Were Integrated During The Second Quarter. Traws Reported a 2Q24 loss of $123.1 million or $(4.87) per share, including a $117.5 million charge for in-process research and development related to the acquisition of Transfynydd. Excluding the charge, net loss would have been around $5.7 million or about $(0.22) per share. The company ended the quarter with $16.4 million in cash, which we expect to fund operations and clinical milestone announcements through the end of 2024.

Influenza Program Is In Phase 1.TRX100 (tivoxavir marboxil) is a cap-dependent endonuclease inhibitor for influenza. Inhibition of this enzyme in the influenza virus inhibits viral replication of both influenza A and B strains. Early dosing studies have shown safety and tolerability, with data to support a single oral dose for therapeutic or prophylactic use. A Phase 1 dose single-dose escalation study is currently in progress.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

QuoteMedia Inc. (QMCI) – Revenue Remains Lackluster

Posted on by cpereira@noblefcm.com


Friday, August 16, 2024

QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Broadridge Financial Systems, JPMorgan Chase, CI Financial, Canaccord Genuity Corp., Hilltop Securities, HD Vest, Stockhouse, Zacks Investment Research, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, FolioFN, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Qtrade Financial, CNW Group, IA Private Wealth, Ally Invest, Inc., Suncor, Virtual Brokers, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Cirano, Equisolve, Stock-Trak, Mergent, Cision, Day Trade Dash and others. Quotestream®, QModTM and Quotestream ConnectTM are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Hans Baldau, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Weak Q2 Results. The company reported revenue of $4.7 million and adjusted EBITDA of $0.5 million, lighter than our estimates of $5.0 million and $0.9 million, respectively. Figure #1 Q2 Variance highlights the company’s results against our expectations. Revenues stayed flat from the first quarter and decreased by 1.0% from the year earlier Q2 2023. 

Lackluster revenue outlook. Management indicated the lackluster revenue trends appear to be continuing into the third quarter in spite of a building pipeline of business. We believe that the company is being buffeted by clients switching to cheaper data alternatives (although this is low margin business) and lower volumes. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

InPlay Oil (IPOOF) – Updating Estimates to Reflect Revised Guidance

Posted on by cpereira@noblefcm.com


Friday, August 16, 2024

InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX Exchange under the symbol IPOOF.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second quarter financial results. InPlay Oil reported second quarter net income of C$5.4 million or C$0.06 per compared to C$4.3 million or C$0.05 per during the prior year period. We had forecast net income of C$3.6 million or C$0.04 per share. Average quarterly production increased 2.2% to 8,657 barrels of oil equivalent per day (boe/d) compared to 8,474 in the second quarter of 2023.

Corporate guidance. InPlay trimmed its 2024 production guidance to a range of 8,700 to 9,000 boe/d from 9,000 to 9,500, and lowered expectations for crude oil prices. Lower production reflects foregone production from a Glauconite well that was drilled but experienced casing failure, downtime, and a decision to bring wells on later in the year. Expense guidance is mostly unchanged on a dollar per barrel of oil equivalent basis. Adjusted funds flow is expected to be in the range of C$80 million to C$85 million compared to prior guidance of C$90 million to C$97 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Conduent Inc. (CNDT) – Nearing the Trough, Looking Towards the Future

Posted on by cpereira@noblefcm.com


Friday, August 16, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 beat. The company delivered solid Q2 with revenue of $828 million, slightly better than our forecast of $812 million, and adj. EBITDA of $35 million, 84% better than our estimate of $19 million. Importantly, we believe the company is nearing the trough of its operating results as its divestiture activity appears to be winding down.

Favorable trends emerging. Importantly, the Commercial segment, the company’s largest by revenue, appears to be trending positively. Management highlighted that new business signings rebounded in Q2. Additionally, the Transportation segment is positioned for sequential revenue growth in the back half of the year, buoyed by a large contract in Australia.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Gold Shines Bright: Outperforming Indexes in Uncertain Times

Posted on by slightbourne@noblecapitalmarkets.com

As global markets continue to navigate choppy waters, one asset class has emerged as a beacon of stability and growth: gold. The precious metal has been on a remarkable upward trajectory, consistently making new highs and outperforming major stock market indexes. This trend has caught the attention of investors, particularly those interested in small-cap opportunities in the gold mining sector.

In recent months, gold prices have surged to record levels, breaking through previous resistance points and establishing new benchmarks. This impressive performance comes against a backdrop of economic uncertainty, inflationary pressures, and geopolitical tensions – factors that have historically driven investors towards safe-haven assets like gold.

The numbers speak for themselves: While the NASDAQ has posted a respectable year-to-date (YTD) gain of 12%, gold has outpaced it with a YTD increase of 16%. Looking at the year-over-year (YOY) performance, the NASDAQ is up 22%, but gold is not far behind with a 21% increase. These figures underscore gold’s resilience and its ability to keep pace with, and even outperform, one of the most dynamic stock market indexes.

Several key drivers are fueling gold’s ascent:

  1. Inflation concerns: With central banks around the world implementing accommodative monetary policies to combat economic slowdowns, fears of inflation have intensified. Gold, long considered a hedge against inflation, has naturally attracted increased investor interest.
  2. Weakening dollar: The US dollar’s relative weakness has made gold more attractive to international investors, as the metal becomes cheaper in other currencies.
  3. Geopolitical tensions: Ongoing conflicts and trade disputes have heightened global uncertainty, prompting investors to seek refuge in gold’s perceived stability.
  4. Low interest rates: With rates remaining at historically low levels, the opportunity cost of holding non-yielding assets like gold has decreased, making it more appealing to investors.

While major indexes like the S&P 500 and Dow Jones Industrial Average have experienced volatility, gold has steadily climbed. Its ability to outpace the NASDAQ’s YTD performance is particularly noteworthy, given the tech-heavy index’s reputation for growth.

This outperformance has significant implications for the small-cap investing landscape, particularly in the gold mining sector. Junior gold miners and exploration companies often exhibit a leveraged relationship to gold prices, meaning their stock prices can move more dramatically than the price of gold itself.

As gold prices rise, many of these smaller companies become increasingly viable, with previously marginal projects suddenly becoming profitable. This dynamic creates exciting opportunities for small-cap investors who are willing to do their due diligence and identify promising junior miners with solid fundamentals and strong growth potential.

However, it’s crucial for investors to approach this sector with caution. While the potential rewards can be substantial, junior gold stocks are known for their volatility. Thorough research, diversification, and a long-term perspective are essential when considering investments in this space.

Looking ahead, many analysts remain bullish on gold’s prospects. The combination of ongoing economic uncertainties, potential inflationary pressures, and the metal’s historical role as a store of value suggest that gold may continue its upward trajectory. This outlook bodes well for both direct investments in gold and strategic positions in carefully selected gold mining stocks.

In conclusion, gold’s stellar performance amidst current market conditions presents a compelling narrative for investors. Its ability to outshine major indexes while providing a hedge against economic uncertainties makes it an attractive option for portfolio diversification. For small-cap investors, the gold mining sector offers intriguing opportunities to capitalize on this trend, provided they approach it with the necessary research and risk management strategies.

As always, investors should consult with financial advisors and conduct thorough research before making investment decisions, especially in the dynamic and potentially volatile world of small-cap gold stocks.

Mars Acquires Pringles Parent Kellanova for $36 Billion in 2024’s Mega Deal

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Mars acquires Kellanova for $36 billion, creating a snacking powerhouse
– Deal combines iconic brands like M&M’s, Snickers, Pringles, and Pop-Tarts
– Merger aims to boost market share and navigate changing consumer trends

Mars Inc. has announced its acquisition of Kellanova for a staggering $36 billion, sending shockwaves through the global snack industry. This landmark deal, the largest of 2024, is set to reshape the landscape of the packaged food sector and create a snacking behemoth that combines some of the world’s most beloved brands.

The all-cash transaction, which values Kellanova at $83.50 per share, represents a significant 33% premium over the company’s recent stock price. This bold move by Mars, the family-owned confectionery giant, signals a strategic push to expand its snacking platform and strengthen its position in an increasingly competitive market.

As consumers continue to reach for convenient, branded snacks despite economic pressures, this merger capitalizes on the enduring appeal of household names. The deal brings together Mars’ iconic candies like M&M’s and Snickers with Kellanova’s popular offerings such as Pringles, Cheez-It, and Pop-Tarts. This diverse portfolio positions the combined entity to cater to a wide range of snacking preferences and occasions.

Mars CEO Poul Weihrauch emphasized the company’s commitment to maintaining price stability, stating, “We hope to be able to absorb more costs in our structure and help alleviate the issues we have in an inflationary environment.” This consumer-friendly approach could help the newly formed snacking powerhouse navigate the challenges of price-sensitive shoppers and increased competition from private label brands.

The merger also presents exciting opportunities for global expansion. Kellanova’s strong presence in Africa opens new doors for Mars to introduce its confectionery products to the continent. Conversely, Mars’ established foothold in China could pave the way for Pringles to significantly expand its reach in the world’s most populous market.

Industry analysts view this deal as a potential catalyst for further consolidation in the packaged food sector. As companies seek to achieve economies of scale and enhance their competitive edge, we may see more strategic acquisitions and mergers in the near future.

However, the road ahead is not without challenges. The combined company will need to navigate changing consumer preferences, including a growing demand for healthier snack options. Mars has indicated that about half of its portfolio will consist of “wholesome” snacks, such as low-calorie Special K, Kind bars, and Nutri-grain, addressing this trend.

Another potential hurdle is the impact of weight loss drugs like Ozempic and Wegovy on snack consumption. While Mars currently has no plans to develop products specifically for users of these medications, the company’s diverse portfolio may help mitigate any potential downturn in certain product categories.

As the deal moves forward, subject to regulatory approvals, the snack industry watches with bated breath. The creation of this new snacking giant is poised to reshape market dynamics, influence product innovation, and potentially redefine the way we indulge in our favorite treats.

With the transaction expected to close in the first half of 2025, consumers and investors alike are eager to see how this sweet merger will transform the future of snacking. As Mars and Kellanova join forces, one thing is certain: the snack aisle will never be the same again.

The NobleCon20 VIP Giveaway – Entry Form

Posted on by cpatches

Please complete the form, in its entirety, to enter the NobleCon20 VIP Giveaway. The winner will be notified on November 1, 2024.

To complete your entry, please provide a valid email address and verify your new Channelchek account by clicking the verification link sent to your email.

Release – LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on LSB

Gross margin increased to 79.5%; product pipeline continues to advance

Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025

GAITHERSBURG, Md., Aug. 15, 2024 /PRNewswire/ — LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the fiscal year ended March 31, 2024 (“Fiscal Year 2024”).

   

Mr. Dave Chenn, Chairman and Interim Chief Executive Officer of the Company, commented, “In Fiscal Year 2024, our revenue was affected by a shortage of finished product inventory, resulting from earlier supply chain disruptions at our YSJA rabies vaccine production facilities. Despite these difficulties, we have successfully implemented operational improvements that have normalized production, and our inventory challenges are now resolved as we enter Fiscal Year 2025. We have maintained our position as a leading rabies vaccine producer in China, and continued to improve our gross margin by emphasizing operational efficiency. We also made significant advancements in our product pipeline during Fiscal Year 2024, progressing our next-generation PIKA rabies vaccine through its ongoing Phase III clinical trial and meeting significant developmental milestones for other pipeline products.”

Mr. Dave Chenn continued, “Looking ahead, our Fiscal Year 2025 strategy will focus on driving revenue growth, controlling expenses, and enhancing profit margins. We are implementing a comprehensive plan that includes cost reductions, organizational restructuring, strengthened internal controls, and strategic resource allocation to key growth areas. Our goal will be to foster innovation, efficiency, stability, and sustainable profitability as we work to build value for our shareholders.”

Ms. Rachel Yu, Interim Chief Financial Officer of the Company, added, “For Fiscal Year 2024, we recorded revenues of RMB573.4 million (US$80.8 million), representing a decrease compared to Fiscal Year 2023 due to persistent supply chain issues affecting raw material availability, manufacturing processes, and overall output capacity which impacted our topline. We recorded a gross profit of RMB455.7 million (US$64.2 million), and our gross margin increased by 1.8 percentage points to 79.5% compared to Fiscal Year 2023. With cash and cash equivalents of RMB246.6 million (US$34.7 million), we will maintain our focus on maximizing long-term shareholder returns by refining our business strategies and leveraging new market opportunities. Looking ahead to Fiscal Year 2025, we anticipate double-digit year-over-year growth in revenues, and expect to achieve breakeven on our bottom line by the time our fiscal year concludes on March 31, 2025.”

Business Updates

YSJATM Rabies Vaccine

LakeShore Biopharma’s marketed vaccine product, YSJATM rabies vaccine, is the first aluminum-free lyophilized rabies vaccine launched in China. Since the Company commenced production at its current GMP-compliant facilities in February 2020, and commercialization of the product in late 2020, market intake of the Company’s YSJA rabies vaccine has been consistent and strong. As of March 31, 2024, LakeShore Biopharma maintained its leadership position as one of the top rabies vaccine producers in China and has sold more than 27.3 million doses of YSJATM rabies vaccines to approximately 1,767 Chinese Center(s) for Disease Control and Prevention (“CDC”) customers, which represents 61.3% of CDC customers in China since October 2020.

Clinical Pipeline

LakeShore Biopharma continues to prioritize and advance its portfolio of innovative product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA YS-ON-001, and PIKA YS-HBV-002.

PIKA Rabies Vaccine

  • In April 2024, the Company announced positive interim results from the ongoing Phase III clinical trial of its next-generation PIKA rabies vaccine in the Philippines and Pakistan. The interim results indicate that the PIKA rabies vaccine has successfully met the primary endpoints of the trial and has the potential to achieve best-in-class accelerated protection and meet the World Health Organization’s goal of a one-week rabies vaccine regimen to replace the conventional three- or four-week regimens. Subject to successful completion of the Phase III clinical trial, the Company plans to submit the New Drug Applications/Biologics License Applications to relevant regulatory authorities throughout Asia, Africa, Europe, and the Americas.

PIKA YS-ON-001

  • PIKA YS-ON-001 is designed as an immunological therapeutical agent against cancers. In 2023, the Company completed the Phase I clinical trial of PIKA YS-ON-001 in China.

PIKA YS-HBV-002

  • In April 2024, the Company announced that its YS-HBV-002, the second generation of immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus infection, had been granted clinical trial approval by the Philippine Food and Drug Administration. In light of the approval, the Company is preparing to initiate a Phase I clinical trial for YS-HBV-002 in the Philippines.

Fiscal Year 2024 Financial Results

Total Revenue

Total revenue was RMB573.4 million (US$80.8 million) in Fiscal Year 2024, compared to RMB687.2 million in the same period of 2023, representing a decrease of 16.6%. This was primarily due to COVID-related disruptions affecting the Company’s manufacturing operations and production, which reduced batch approvals and doses available for sale. This impact was partially offset by an increase in the product price of the YSJA rabies vaccine of approximately RMB2.9 per dose.

Gross Profit

Gross profit in Fiscal Year 2024 was RMB455.7 million (US$64.2 million), representing a 79.5% gross margin, compared to RMB533.8 million, or a 77.7% gross margin, in the same period of 2023. The improvement in gross margin was primarily due to the increase in unit price of the YSJA rabies vaccine, and a decrease in unit cost resulting from lowered delivery costs and an increase in production batches.

Selling and Marketing Expenses

Selling and marketing expenses in Fiscal Year 2024 were RMB301.3 million (US$42.5 million), compared to RMB272.9 million in the same period of 2023. This change was primarily due to an increase in promoting and marketing service fees to continuously promote the YSJA rabies vaccine.

General and Administrative Expenses

General and administrative expenses in Fiscal Year 2024 were RMB140.1 million (US$19.7 million), compared to RMB72.9 million in the same period of 2023. This change was primarily attributable to increases in legal fees, auditing fees, directors & officers liability insurance costs, and employee benefits.

Research and Development Expenses

Research and development expenses in Fiscal Year 2024 were RMB302.8 million (US$42.7 million), compared to RMB318.7 million in the same period of 2023. The change was primarily driven by decreases in testing fees, clinical trial fees, and consulting service fees related to the development of the Company’s COVID-19 vaccine, and decreases in employee benefits as a result of staffing optimizations.

Impairment Loss on Inventory, Property, Plant and Equipment, and Other Assets

Impairment loss on inventory, property, plant and equipment (“PP&E”), and other assets in Fiscal Year 2024 was RMB157.4 million (US$22.2 million), compared to RMB8.7 million in the same period of 2023. The change was primarily attributable to 1) impairment loss on inventory impacted by COVID-related disruptions affecting the Company’s manufacturing operations and production and raw materials used in the research and development of the Company’s COVID-19 vaccine, and 2) impairment loss on PP&E related to COVID-19 vaccine equipment.

Net Loss

Net loss for Fiscal Year 2024 was RMB433.5 million (US$61.1 million), compared with RMB145.5 million in the same period of 2023.

Balance Sheet

As of March 31, 2024, the Company had cash and cash equivalents of RMB246.6 million (US$34.7 million), compared with RMB370.4 million as of March 31, 2023.

Business Outlook

The Company anticipates double-digit year-over-year revenue growth and expects to achieve breakeven in Fiscal Year 2025.

The above outlook is based on information available as of the date of this press release and reflects the Company’s current and preliminary expectations regarding its business situation and market conditions. The outlook is subject to changes, especially given uncertainties and situations related to market competitive dynamics and regulatory policies, etc.

About LakeShore Biopharma 

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit https://investor.lakeshorebio.com/.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.095 to US$1.00, the exchange rate set forth in the central parity rate release of the People’s Bank of China on March 31, 2024.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of LakeShore Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, LakeShore Biopharma’s ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “potential,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “goal,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma’s management and are not predictions of actual performance.

LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading “Risk Factors” in the company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.

Investor Relations Contact

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com 

Click here for full report